Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate
Autor: | Kallirroi I Kalantzi, Ioannis Goudevenos, Andromachi A Dimitriou, Alexandros D. Tselepis, Ioannis Ntalas, Maria E. Tsoumani |
---|---|
Rok vydání: | 2011 |
Předmět: |
Male
medicine.medical_specialty Acute coronary syndrome Ticlopidine Platelet Aggregation medicine.medical_treatment Loading dose law.invention Randomized controlled trial law Internal medicine medicine Humans Pharmacology (medical) In patient Platelet cardiovascular diseases Acute Coronary Syndrome Aged Pharmacology business.industry Percutaneous coronary intervention General Medicine Middle Aged medicine.disease Clopidogrel Conventional PCI Purinergic P2Y Receptor Antagonists Cardiology Female business Platelet Aggregation Inhibitors circulatory and respiratory physiology medicine.drug |
Zdroj: | Expert Opinion on Pharmacotherapy. 13:149-158 |
ISSN: | 1744-7666 1465-6566 |
Popis: | The efficacy of clopidogrel therapy in patients with an acute coronary syndrome (ACS) has been established using the clopidogrel hydrogen sulfate (CHS) formulation. In this study we compared the antiplatelet effectiveness of a generic clopidogrel salt, clopidogrel besylate (CB), with the original CHS in patients with an ACS.Ninety-six ACS patients were randomized to receive a 600-mg loading dose of either CHS (n = 45) or CB (n = 51), followed by 75 mg/day. Sixty-eight patients underwent a percutaneous coronary intervention (PCI), whereas 28 were treated conservatively. Platelet aggregatory response, vasodilator-stimulated phosphoprotein (VASP) phosphorylation, P-selectin expression and platelet-leucocyte conjugates were determined before clopidogrel loading (baseline), as well as at 5 days and at 1 month afterwards.No difference in the clopidogrel response variability was observed between patients receiving CHS or CB either at 5 days or at 1 month of follow-up. Similarly, no difference in the inhibition of platelet aggregation, P-selectin expression or in the platelet-leucocyte conjugates was observed between CHS and CB group during the follow-up.There is no overall significant difference in the antiplatelet efficacy between CB and CHS during their administration in ACS patients for up to 1 month after the episode. |
Databáze: | OpenAIRE |
Externí odkaz: |